Literature DB >> 11536152

Induction of antigen-specific human CD4(+) T cell anergy by peripheral blood DC2 precursors.

M Kuwana1, J Kaburaki, T M Wright, Y Kawakami, Y Ikeda.   

Abstract

Dendritic cells (DC) are antigen (Ag)-presenting cells that are essential for initiation of T cell-dependent immunity, and distinct DC subsets are known to direct different classes of immune responses. DC2 precursors (pDC2) or plasmacytoid DC were recently identified as a Th2-skewing and IFN-alpha-producing human DC subset. Here, we demonstrate that pDC2 enriched from human peripheral blood have a capacity to induce an anergic state in human Ag-specific CD4(+) T cell lines. Tetanus toxoid-specific T cell lines incubated with tetanus toxoid-pulsed autologous pDC2 failed to proliferate in secondary cultures with optimal Ag stimulation. T cell anergy induction required TCR engagement with Ag/MHC complex presented on pDC2. T cells rendered anergic lost IL-2 production but produced IFN-gamma and IL-10 upon stimulation. The pDC2-induced unresponsiveness was completely or partially reversible when a high concentration of exogenous IL-2 was added in the secondary cultures. Autoreactive CD4(+) T cell clones specific for topoisomerase I derived from a patient with scleroderma were also rendered anergic after co-culture with topoisomerase I-pulsed autologous pDC2,resulting in failure to proliferate or provide help to B cells. These results suggest that pDC2 are involved in maintenance of peripheral T cell tolerance and have potential for use in the suppression of pathogenic T cell responses in autoimmune diseases and organ transplantation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536152     DOI: 10.1002/1521-4141(200109)31:9<2547::aid-immu2547>3.0.co;2-j

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  30 in total

1.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

Review 2.  Dendritic cells, T cell tolerance and therapy of adverse immune reactions.

Authors:  P A Morel; M Feili-Hariri; P T Coates; A W Thomson
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

3.  Liver tolerance mediated by antigen presenting cells: fact or fiction?

Authors:  A H Lau; A de Creus; L Lu; A W Thomson
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

4.  Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells.

Authors:  Latt Latt Aung; Andrew Brooks; Steven A Greenberg; Michael L Rosenberg; Suhayl Dhib-Jalbut; Konstantin E Balashov
Journal:  J Neuroimmunol       Date:  2012-06-09       Impact factor: 3.478

Review 5.  Plasmacytoid dendritic cells: linking innate and adaptive immunity.

Authors:  Kelli McKenna; Anne-Sophie Beignon; Nina Bhardwaj
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 6.  Functional diversity and plasticity of human dendritic cell subsets.

Authors:  Tomoki Ito; Yong-Jun Liu; Norimitsu Kadowaki
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

7.  A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes.

Authors:  Hong Zhang; Josh D Gregorio; Toru Iwahori; Xiangyue Zhang; Okmi Choi; Lorna L Tolentino; Tyler Prestwood; Yaron Carmi; Edgar G Engleman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-06       Impact factor: 11.205

8.  The cross-regulatory relationship between human dendritic and regulatory T cells and its role in type 1 diabetes mellitus.

Authors:  Hsuen-Wen Chang; Yen-Hung Chow; Pele Chong; Charles Sia
Journal:  Rev Diabet Stud       Date:  2007-08-10

9.  Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood.

Authors:  Xueqin Chen; Levi H C Makala; Yulan Jin; Diane Hopkins; Andy Muir; Nikhil Garge; Robert H Podolsky; Jin-Xiong She
Journal:  Clin Immunol       Date:  2008-09-30       Impact factor: 3.969

10.  Clinical uses of GM-CSF, a critical appraisal and update.

Authors:  Martha Arellano; Sagar Lonial
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.